How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,835 results for

"covid 19" OR "novel coronavirus"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) POSITION ARTICLE AND GUIDELINE Open Access A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Ying-Hui Jin 1 , Lin Cai 2 , Zhen-Shun Cheng 3 , Hong Cheng 4 , Tong Deng 1,5 , Yi-Pin Fan 6,7 , Cheng Fang 1 , Di Huang 1 , Lu-Qi Huang 6,7 , Qiao Huang 1 , Yong Han 2 ,BoHu 8 , Fen Hu 8 (...) 1,18* , Yong-Yan Wang 6,7* , Xing-Huan Wang 1,2* , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM) Abstract In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV)” by the World Health Organization (WHO) on 12 January 2020. For it is a never been

2020 Covid-19 Ad hoc guidelines

22. Risk communication and community engagement (RCCE) readiness and response to the 2019 novel coronavirus (??2019-nCoV)??

Risk communication and community engagement (RCCE) readiness and response to the 2019 novel coronavirus (??2019-nCoV)?? Risk communication and community engagement (RCCE) readiness and response to the 2019 novel coronavirus (‎‎2019-nCoV)‎‎ WHO Regional websites / / Risk communication and community engagement (RCCE) readiness and response to the 2019 novel coronavirus (‎‎2019-nCoV)‎‎ © 2020

2020 WHO Coronavirus disease (COVID-19) Pandemic

23. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected

Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected WHO Regional websites / / Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected © 2020

2020 WHO Coronavirus disease (COVID-19) Pandemic

24. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts

Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts WHO Regional websites / / Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts © 2020

2020 WHO Coronavirus disease (COVID-19) Pandemic

25. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected WHO Regional websites / / Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected © 2020

2020 WHO Coronavirus disease (COVID-19) Pandemic

26. Novel coronavirus (2019-nCoV): guidance to assist professionals in advising the general public

Novel coronavirus (2019-nCoV): guidance to assist professionals in advising the general public COVID-19: guidance to assist professionals in advising the general public - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search The UK has left the EU Guidance COVID-19: guidance to assist (...) professionals in advising the general public Advice on how to prevent spread of the infection, what symptoms to look for and what to do. Published 1 February 2020 Last updated 6 February 2020 — From: Documents HTML Details This guidance will assist professionals in providing advice to the public on how to prevent the spread of COVID-19 infection, what symptoms to look for, and what to do if they become unwell in a variety of settings. There may be further information specific to each country in the United

2020 Public Health England

27. Novel coronavirus (2019-nCoV): self-isolation for patients undergoing testing

Novel coronavirus (2019-nCoV): self-isolation for patients undergoing testing COVID-19: self-isolation for patients undergoing testing - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search The UK has left the EU Guidance COVID-19: self-isolation for patients undergoing testing Guidance (...) for how patients should self-isolate while awaiting results of laboratory testing for SARS-CoV-2. Published 31 January 2020 Last updated 31 January 2020 — From: Documents HTML HTML HTML Details This guidance provides advice for individuals who are awaiting results from diagnostic testing for COVID-19 and do not require admission to hospital. COVID-19 was previously referred to as Wuhan novel coronavirus. There may be further information specific to each country in the United Kingdom, as this guidance

2020 Public Health England

28. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts

Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts 1 Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts Interim guidance 17 March 2020 Background WHO has developed this interim guidance to meet the need for recommendations on safe home care for patients with suspected COVID-19 who present with mild symptoms a and on public health measures related to the management (...) of their contacts. This document was adapted from the interim guidance on Middle East respiratory syndrome coronavirus (MERS-CoV) infection that was published in June 2018 1 and is informed by evidence-based guidelines published by WHO, including Infection prevention and control of epidemic- and pandemic- prone acute respiratory diseases in health care, 2 and based on current information on COVID-19. This rapid advice has been updated with the latest information and is intended to guide public health

2020 WHO Coronavirus disease (COVID-19) Pandemic

29. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Full Text available with Trip Pro

2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are needed.To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD.This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were (...) compared with the general population in the Madrid region.Through April 8, 12 of 1918 IBD patients were diagnosed with COVID-19. The average age was 52 years, 75% of the patients were female and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these four with combined therapy (33%). Eight patients (66%) required hospitalisation (one intensive care unit admission, and two deaths), and four patients were isolated at home. Nine patients had

2020 Alimentary Pharmacology & Therapeutics

30. Novel Coronavirus Disease 2019 (COVID-19) Pneumonia Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section Computed Tomography Features During Recovery. Full Text available with Trip Pro

Novel Coronavirus Disease 2019 (COVID-19) Pneumonia Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section Computed Tomography Features During Recovery. Our objective was to retrospectively analyze the evolution of clinical features and thin-section computed tomography (CT) imaging of novel coronavirus disease 2019 (COVID-19) pneumonia in 17 discharged patients.Serial thin-section CT scans of 17 discharged patients with COVID-19 were obtained during recovery

2020 Clinical Infectious Diseases

31. Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China. Full Text available with Trip Pro

Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China. To assess the case fatality risk (CFR) of COVID-19 in mainland China, stratified by region and clinical category, and estimate key time-to-event intervals.We collected individual information and aggregated data on COVID-19 cases from publicly available official sources from December 29, 2019 to April 17, 2020. We accounted for right-censoring to estimate the CFR and explored the risk factors (...) that of mild-to-severe patients. Older age (OR 1.14 per year; 95%CI: 1.11-1.16), and being male (OR 1.83; 95%CI: 1.10-3.04) were risk factors for mortality. The time from symptom onset to first healthcare consultation, time from symptom onset to laboratory confirmation, and time from symptom onset to hospitalization were consistently longer for deceased patients than for those who recovered.Our CFR estimates based on laboratory-confirmed cases ascertained in mainland China suggest that COVID-19 is more

2020 Clinical Infectious Diseases

32. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Full Text available with Trip Pro

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). The emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. The current method of detection involves a quantitative polymerase chain reaction (qPCR)-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False-negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission (...) . We aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19.The host humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, was examined by using an ELISA-based assay on the recombinant viral nucleocapsid protein. 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but with typical manifestation). The diagnostic value

2020 Clinical Infectious Diseases

33. Prospective study comparing deep-throat saliva with other respiratory tract specimens in the diagnosis of novel coronavirus disease (COVID-19). Full Text available with Trip Pro

Prospective study comparing deep-throat saliva with other respiratory tract specimens in the diagnosis of novel coronavirus disease (COVID-19). Self-collected specimens has been advocated to avoid infectious exposure to healthcare workers. Self-induced sputum in those with a productive cough, and saliva in those without a productive cough have been proposed, but sensitivity remains uncertain.We performed a prospective study in two regional hospitals in Hong Kong.We prospectively examined 563

2020 Journal of Infectious Diseases

34. Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. Full Text available with Trip Pro

Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. Knowledge on the epidemiological features and transmission patterns of COVID-19 is accumulating. Detailed line-list data with household settings can advance the understanding of COVID-19 transmission dynamics.A unique database with detailed demographic characteristics, travel history, social relationships (...) , and epidemiological timelines for 1,407 transmission pairs that formed 643 transmission clusters in mainland China was reconstructed from 9,120 COVID-19 confirmed cases reported during January 15 - February 29, 2020. Statistical model fittings were used to identify the super-spreaders and estimate serial interval distributions. Age and gender-stratified hazard of infection were estimated for household versus non-household transmissions.There were 34 primary cases identified as super-spreaders, with 5 super

2020 Clinical Infectious Diseases

35. Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19). Full Text available with Trip Pro

Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19). We present a case of an abducens nerve palsy in a previously healthy young man in the setting of SARS-CoV-2 infection. Magnetic resonance imaging obtained 5 weeks after the onset of diplopia demonstrated an atrophic left lateral rectus muscle, which was hyperintense on T2 weighting, consistent with denervation. Although the mechanism of the nerve palsy remains unclear, it is suspected to be related to his (...) viral illness, because the patient had no preexisting vascular risk factors or evidence of other neurologic disease on neuroimaging. Cranial nerve palsies may represent part of the neurologic spectrum of COVID-19.Copyright © 2020 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

2020 JAAPOS - Journal of the American Association for Pediatric Ophthalmology and Strabismus

36. COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. Full Text available with Trip Pro

COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. Recent retrospective studies from Wuhan, China suggest Novel Coronavirus Disease 2019 (COVID-19) may be associated with a hypercoagulable state and increased risk for venous thromboembolism. The overlap in the signs and symptoms of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS) and COVID-19 with concurrent pulmonary embolism creates a diagnostic challenge (...) for emergency medicine physicians in patients already at risk for renal impairment. However, identifying features atypical for COVID-19 alone may play a role in the judicious use of Computed Tomography Angiography among these patients. Hemoptysis is seen in roughly 13% of pulmonary embolism cases and infrequently reported among COVID-19 infections. Additionally, the presence of right heart strain on electrocardiography (EKG) is a well described clinical presentations of pulmonary embolism not reported

2020 American Journal of Emergency Medicine

37. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. Full Text available with Trip Pro

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019 (COVID-19), from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma were retrospectively found to have had COVID-19 at the time of the operation. These two cases thus provide important (...) first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that apart from the tumors, the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Because both patients did not exhibit symptoms of pneumonia at the time of operation, these changes likely represent an early phase of the lung pathology

2020 Journal of Thoracic Oncology

38. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Full Text available with Trip Pro

Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. There was much evidence suggesting that the serum lactate dehydrogenase (LDH) levels reflect the extent of various pathophysiological processes. However, the current information about dynamic change of LDH in COVID-19 pneumonia has not been well investigated.Study was performed in 87 cases confirmed by COVID-19 infection. The serum LDH levels were determined (...) to radiographic absorption (5.57 ± 0.65 days, r = 0.53, P < 0.05). Applying the cut-off value of the increase in LDH has good specificity to predict disease progression.Serum LDH was validated for its potential usefulness as markers for evaluating clinical severity and monitoring treatment response in COVID-19 pneumonia.

2020 Respiratory research

39. Effects of respiratory rehabilitation on patients with novel coronavirus (COVID-19) pneumonia in the rehabilitation phase: protocol for a systematic review and meta-analysis. Full Text available with Trip Pro

Effects of respiratory rehabilitation on patients with novel coronavirus (COVID-19) pneumonia in the rehabilitation phase: protocol for a systematic review and meta-analysis. The recent viral pneumonia caused by the COVID-19 has gained the attention of the people all over the world. We aim to investigate the effects of respiratory rehabilitation therapy on patients infected with the novel coronavirus by conducting a systematic review and meta-analysis.This systematic review and meta-analysis

2020 BMJ open

40. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. Full Text available with Trip Pro

Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the WHO on 11 March 2020. Due to the unknown nature of the disease and the lack of specific drugs, several potential treatments were used for patients. This systematic review and meta-analysis (...) will evaluate studies of the effects of favipiravir in COVID-19 pneumonia.We will search electronic databases including LitCovid hub, PubMed, Scopus, ISI Web of Sciences, Cochrane and Embase using keywords related to COVID-19 and favipiravir. We will search the reference lists of all included studies and reviews. We will also search for clinical trial registries, such as ClinicalTrials.gov, for the ongoing clinical trials. All randomised clinical trials investigating the safety and efficacy of favipiravir

2020 BMJ open

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>